1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Microspheres containing bupivacaine loaded to about 75 percent by weight with bupivacaine are prepared, in a percent loading of about 0.05 percent, by weight, using the methods described in EXAMPLES 1-3 or EXAMPLES 4-9, above. In addition, microspheres containing added epinephrine, in a percent loadings of 0.001 percent, 0.05 percent and 1 percent, without bupivacaine, are also prepared according to EXAMPLES 1-3 or EXAMPLES 4-9, above. are prepared, in a percent loading of about 0.05 percent, by weight In addition, microspheres containing

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Microspheres containing bupivacaine loaded to about 75 percent by weight with bupivacaine are prepared, in a percent loading of about 0.05 percent, by weight, using the methods described in EXAMPLES 1-3 or EXAMPLES 4-9, above. In addition, microspheres containing added epinephrine, in a percent loadings of 0.001 percent, 0.05 percent and 1 percent, without bupivacaine, are also prepared according to EXAMPLES 1-3 or EXAMPLES 4-9, above. are prepared, in a percent loading of about 0.05 percent, by weight In addition, microspheres containing

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Microspheres containing bupivacaine loaded to about 75 percent by weight with bupivacaine are prepared, in a percent loading of about 0.05 percent, by weight, using the methods described in EXAMPLES 1-3 or EXAMPLES 4-9, above. In addition, microspheres containing added epinephrine, in a percent loadings of 0.001 percent, 0.05 percent and 1 percent, without bupivacaine, are also prepared according to EXAMPLES 1-3 or EXAMPLES 4-9, above. are prepared, in a percent loading of about 0.05 percent, by weight In addition, microspheres containing

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Microspheres containing bupivacaine loaded to about 75 percent by weight with bupivacaine are prepared, in a percent loading of about 0.05 percent, by weight, using the methods described in EXAMPLES 1-3 or EXAMPLES 4-9, above. In addition, microspheres containing added epinephrine, in a percent loadings of 0.001 percent, 0.05 percent and 1 percent, without bupivacaine, are also prepared according to EXAMPLES 1-3 or EXAMPLES 4-9, above. are prepared, in a percent loading of about 0.05 percent, by weight In addition, microspheres containing

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A uniform mixture of DMS and bupivacaine was formed by combining DMS dissolved in 95% ethanol with bupivacaine dissolved in 95% ethanol. The solution was air-dried under the hood at room temperature until the ethanol evaporated and left behind a well-dispersed mixture of dry crystalline DMS and bupivacaine. The crystalline mixture was pulverized under mortar and pestle and combined with copolymer. The rest of the procedures followed those described for CHP PLAMs. All DMS/bupivacaine PLAMs were synthesized using large bore Teflon® tubing. The solution was air-dried under the hood at room temperature until the ethanol evaporated left behind a well-dispersed mixture of dry crystalline DMS and bupivacaine

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A composition suitable for administration in vaginal suppository form 1a prepared by weighing 2 mg of finely divided polynucleotide medicinal substance into a tared container, adding 10 ml of 0.5% bupivacaine HCl in purified water, to make a total of 10 g, and dissolving or mixing depending on the solubility of the medicinal substance; 70 g of glycerin is added and mixed; 20 g of granular gelatin is then added and the composition heated carefully on a steam bath until the gelatin is dissolved. The melted mixture is poured into chilled molds to yield 20 vaginal suppositories of 6 grams each containing 100 mcg of polynucleotide medicinal substance in admixture with 2.5 mg bupivacaine. dissolving mixing mixed 20 g of granular gelatin is then added the composition heated carefully on a steam bath until the gelatin is dissolved The melted mixture is poured into chilled molds

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A uniform mixture of DMS and bupivacaine was formed by combining DMS dissolved in 95% ethanol with bupivacaine dissolved in 95% ethanol. The solution was air-dried under the hood at room temperature until the ethanol evaporated and left behind a well-dispersed mixture of dry crystalline DMS and bupivacaine. The crystalline mixture was pulverized under mortar and pestle and combined with copolymer. The rest of the procedures followed those described for CHP PLAMs. All DMS/bupivacaine PLAMs were synthesized using large bore Teflon® tubing. The solution was air-dried under the hood at room temperature until the ethanol evaporated left behind a well-dispersed mixture of dry crystalline DMS and bupivacaine

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A composition suitable for administration in vaginal suppository form 1a prepared by weighing 2 mg of finely divided polynucleotide medicinal substance into a tared container, adding 10 ml of 0.5% bupivacaine HCl in purified water, to make a total of 10 g, and dissolving or mixing depending on the solubility of the medicinal substance; 70 g of glycerin is added and mixed; 20 g of granular gelatin is then added and the composition heated carefully on a steam bath until the gelatin is dissolved. The melted mixture is poured into chilled molds to yield 20 vaginal suppositories of 6 grams each containing 100 mcg of polynucleotide medicinal substance in admixture with 2.5 mg bupivacaine. dissolving mixing mixed 20 g of granular gelatin is then added the composition heated carefully on a steam bath until the gelatin is dissolved The melted mixture is poured into chilled molds

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Bupivacaine hydrochloride (Sigma-Aldrich Corporation, St. Louis, Mo.) was dissolved in deionized (DI) water at a concentration of 40 mg/ml (saturation). A calculated amount of sodium hydroxide (in the form of 1 N solution) was added to the solution and the pH of the final mixture was adjusted to 10 to precipitate the Bupivacaine base. The precipitated product was filtered, and further washed with DI water at least three times. The precipitated product was dried at ca. 40° C. in vacuum for 24 hours. to precipitate the Bupivacaine base The precipitated product was filtered further washed with DI water at least three times The precipitated product was dried at ca. 40° C. in vacuum for 24 hours